Table 2.
Cox regression analysis for variables associated with 90-day mortality in patients with HBV-ACLF
| Variables | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR 95%(CI) |
P value | Beta coefficient | HR 95%(CI) |
P value | |
| TBIL (μmol/L) |
1.005 (1.004–1.005) |
< 0.001 | 0.003 |
1.002 (1.001–1.003) |
< 0.001 |
| Cr (μmol/L) |
1.008 (1.005–1.010) |
< 0.001 | 0.003 |
1.003 (1.001–1.005) |
0.001 |
| Cyst-c (mg/L) |
1.055 (1.014–1.097) |
0.008 | |||
| Serum Na+(mmol/L) |
0.981 (0.959–1.004) |
0.112 | |||
| INR |
1.488 (1.342–1.651) |
< 0.001 | 0.317 |
1.318 (1.163–1.494) |
< 0.001 |
| PTA (%) |
0.973 (0.959–0.988) |
< 0.001 | |||
| WBC (109/L) |
1.068 (1.043–1.094) |
< 0.001 | |||
| Neutrophils (109/L) |
1.082 (1.055–1.110) |
< 0.001 | |||
| Monocytes(109/L) |
1.080 (0.997–1.170) |
0.060 | |||
| Lymphocytes(109/L) |
0.856 (0.640–1.144) |
0.293 | |||
| RDW (%) |
1.112 (1.075–1.15) |
< 0.001 | 0.053 |
1.047 (1.009–1.086) |
0.015 |
| NLR |
1.053 (1.038–1.068) |
< 0.001 | 0.027 |
1.027 (1.009–1.046) |
0.003 |
| MLR |
1.057 (1.007–1.109) |
0.025 | |||
| PLR |
1.003 (1.001–1.005) |
0.001 | |||
| RLR |
1.016 (1.007–1.026) |
0.001 | |||
| HE | 1.221 | ||||
| (1.101–1.353) | < 0.001 | ||||
| Bacterial infection | 0.55 | ||||
| (0.383–0.785) | 0.001 | ||||
TBIL total bilirubin, ALB albumin, Cr creatinine, Cyst-c Cystatin c, Serum Na+ serum sodium, PT prothrombin time, INR international normalized ratio, PTA prothrombin activity, WBC white blood cell count, RDW red blood cell distribution width, NLR neutrophil/lymphocyte ratio, MLR monocyte/lymphocyte ratio, PLR platelet/lymphocyte ratio, RLR RDW/lymphocyte ratio, HE Hepatic encephalopathy, HBV-ACLF hepatitis B virus related acute-on-chronic liver failure